Supplementary material 4: Included studies for pooled ROMs, RRs, and diagnostic indicators.

1. Studies included in ROM method

Apostolova, L. G., Hwang, K. S., Avila, D., et al. Brain amyloidosis ascertainment from cognitive, imaging, and peripheral blood protein measures [J].Neurology,2015, 84(7): 729-737.

Blasko, I., Jellinger, K., Kemmler, G., et al. Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine [J].Neurobiol Aging,2008, 29(1): 1-11.

Blazhenets, G., Frings, L., Ma, Y., et al. Validation of the Alzheimer Disease Dementia Conversion-Related Pattern as an ATN Biomarker of Neurodegeneration [J].Neurology,2021, 96(9): e1358-e1368.

Cammarata, S., Borghi, R., Giliberto, L., et al. Amyloid-beta(42) Plasma Levels are Elevated in Amnestic Mild Cognitive Impairment [J].Journal of alzheimers disease,2009, 18(2): 267-271.

Chen, T. B., Lai, Y. H., Ke, T. L., et al. Changes in Plasma Amyloid and Tau in a Longitudinal Study of Normal Aging, Mild Cognitive Impairment, and Alzheimer's Disease [J].Dementia and Geriatric Cognitive Disorders,2020, 48(3-4): 180-195.

Cheng, Y. W., Chiu, M. J., Chen, Y. F., et al. The contribution of vascular risk factors in neurodegenerative disorders: From mild cognitive impairment to Alzheimer's disease [J].Alzheimer's Research and Therapy,2020, 12(1): 91.

Cicognola, C., Janelidze, S., Hertze, J., et al. Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment [J].Alzheimers Res Ther,2021, 13(1): 68.

Darmanthé, N., Tabatabaei-Jafari, H., & Cherbuin, N. Combination of plasma neurofilament light chain and mini-mental state examination score predicts progression from mild cognitive impairment to alzheimer's disease within 5 years [J].Journal of Alzheimer's disease,2021, 82(3): 951-964.

Fei, M., Jianghua, W., Rujuan, M., et al. The relationship of plasma Aβ levels to dementia in aging individuals with mild cognitive impairment [J].Journal of the Neurological Sciences,2011, 305(1-2): 92-96.

Forlenza, O. V., Miranda, A. S., Guimar, I., et al. Decreased Neurotrophic Support is Associated with Cognitive Decline in Non-Demented Subjects [J].J Alzheimers Dis,2015, 46(2): 423-429.

Giannisis, A., Al-Grety, A., Carlsson, H., et al. Plasma apolipoprotein E levels in longitudinally followed patients with mild cognitive impairment and Alzheimer's disease [J].Alzheimers Res Ther,2022, 14(1): 115.

Hanon, O., Vidal, J. S., Lehmann, S., et al. Plasma amyloid beta predicts conversion to dementia in subjects with mild cognitive impairment: The BALTAZAR study [J].Alzheimer's and Dementia,2022, 18(12): 2537-2550.

Hansson, O., Zetterberg, H., Vanmechelen, E., et al. Evaluation of plasma Aβ40 and Aβ42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment [J].Neurobiology of aging,2010, 31(3): 357-367.

Janelidze, S., Bali, D., Ashton, N. J., et al. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer's disease [J].Brain,2023, 146(4): 1592-1601.

Janelidze, S., Mattsson, N., Palmqvist, S., et al. Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia [J].Nat Med,2020, 26(3): 379-386.

Kivisäkk, P., Carlyle, B. C., Sweeney, T., et al. Plasma biomarkers for diagnosis of Alzheimer's disease and prediction of cognitive decline in individuals with mild cognitive impairment [J].Frontiers in Neurology,2023, 14: 1069411.

Kivisakk, P., Magdamo, C., Trombetta, B. A., et al. Plasma biomarkers for prognosis of cognitive decline in patients with mild cognitive impairment [J].Brain communications,2022, 4(4): fcac155.

Lehmann, S., Schraen-Maschke, S., Vidal, J. S., et al. Plasma phosphorylated tau 181 predicts amyloid status and conversion to dementia stage dependent on renal function [J].Journal of neurology, neurosurgery and psychiatry,2023, 94(6): 411-419.

Lopez, O. L., Kuller, L. H., Mehta, P. D., et al. Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study [J].Neurology,2008, 70(19 PART 1): 1664-1671.

Pérez-Grijalba, V., Romero, J., Pesini, P., et al. Plasma Aβ42/40 Ratio Detects Early Stages of Alzheimer's Disease and Correlates with CSF and Neuroimaging Biomarkers in the AB255 Study [J].Journal of prevention of alzheimer's disease,2019, 6(1): 34-41.

Pichet Binette, A., Palmqvist, S., Bali, D., et al. Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer's dementia in mild cognitive impairment patients [J].Alzheimers Res Ther,2022, 14(1): 46.

Shen, X. N., Huang, Y. Y., Chen, S. D., et al. Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer's amyloid, tau and FDG PET status [J].Translational psychiatry,2021, 11(1): 585.

Silva-Spínola, A., Lima, M., Leitão, M. J., et al. Blood biomarkers in mild cognitive impairment patients: Relationship between analytes and progression to Alzheimer disease dementia [J].Eur J Neurol,2023, 30(6): 1565-1573.

Simrén, J., Leuzy, A., Karikari, T. K., et al. The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease [J].Alzheimer's and Dementia,2021, 17(7): 1145-1156.

Toledo, J. B., Vanderstichele, H., Figurski, M., et al. Factors affecting A beta plasma levels and their utility as biomarkers in ADNI [J].Acta Neuropathologica,2011, 122(4): 401-413.

Wang, C., Cui, Y., Yang, J., et al. Combining serum and urine biomarkers in the early diagnosis of mild cognitive impairment that evolves into Alzheimer's disease in patients with the apolipoprotein E ε4 genotype [J].Biomarkers,2015, 20(1): 84-88.

Xiao, Z., Wu, W., Ma, X., et al. Plasma Aβ42/Aβ40 and p-tau181 Predict Long-Term Clinical Progression in a Cohort with Amnestic Mild Cognitive Impairment [J].Clinical Chemistry,2022, 68(12): 1552-1563.

Xie, B., Liu, Z., Jiang, L., et al. Increased Serum miR-206 Level Predicts Conversion from Amnestic Mild Cognitive Impairment to Alzheimer's Disease: A 5-Year Follow-up Study [J].J Alzheimers Dis,2017, 55(2): 509-520.

2. Studies included in pooled relative risks (RRs)

Cullen, N. C., Leuzy, A., Palmqvist, S., et al. Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations [J].Nat Aging,2021, 1(1): 114-123.

Darmanthé, N., Tabatabaei-Jafari, H., & Cherbuin, N. Combination of plasma neurofilament light chain and mini-mental state examination score predicts progression from mild cognitive impairment to alzheimer's disease within 5 years [J].Journal of Alzheimer's disease,2021, 82(3): 951-964.

Fei, M., Jianghua, W., Rujuan, M., et al. The relationship of plasma Aβ levels to dementia in aging individuals with mild cognitive impairment [J].Journal of the Neurological Sciences,2011, 305(1-2): 92-96.

Hanon, O., Vidal, J. S., Lehmann, S., et al. Plasma amyloid beta predicts conversion to dementia in subjects with mild cognitive impairment: The BALTAZAR study [J].Alzheimer's and Dementia,2022, 18(12): 2537-2550.

Hansson, O., Zetterberg, H., Vanmechelen, E., et al. Evaluation of plasma Aβ40 and Aβ42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment [J].Neurobiology of aging,2010, 31(3): 357-367.

Janelidze, S., Mattsson, N., Palmqvist, S., et al. Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia [J].Nat Med,2020, 26(3): 379-386.

Karikari, T. K., Benedet, A. L., Ashton, N. J., et al. Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative [J].Mol Psychiatry,2021, 26(2): 429-442.

Kiddle, S. J., Sattlecker, M., Proitsi, P., et al. Candidate blood proteome markers of Alzheimer's disease onset and progression: A systematic review and replication study [J].Journal of Alzheimer's disease,2014, 38(3): 515-531.

Lehmann, S., Schraen-Maschke, S., Vidal, J. S., et al. Plasma phosphorylated tau 181 predicts amyloid status and conversion to dementia stage dependent on renal function [J].Journal of neurology, neurosurgery and psychiatry,2023, 94(6): 411-419.

Lui, J. K., Laws, S. M., Li, Q.-X., et al. Plasma Amyloid-beta as a Biomarker in Alzheimer's Disease: The AIBL Study of Aging [J].Journal of alzheimers disease,2010, 20(4): 1233-1242.

Mielke, M. M., Hagen, C. E., Wennberg, A. M. V., et al. Association of plasma total tau level with cognitive decline and risk of mild cognitive impairment or dementia in the Mayo Clinic study on aging [J].JAMA neurology,2017, 74(9): 1073-1080.

Palmqvist, S., Tideman, P., Cullen, N., et al. Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures [J].Nat Med,2021, 27(6): 1034-1042.

Pérez-Grijalba, V., Romero, J., Pesini, P., et al. Plasma Aβ42/40 Ratio Detects Early Stages of Alzheimer's Disease and Correlates with CSF and Neuroimaging

Biomarkers in the AB255 Study [J].Journal of prevention of alzheimer's disease,2019, 6(1): 34-41.

Pichet Binette, A., Palmqvist, S., Bali, D., et al. Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer's dementia in mild cognitive impairment patients [J].Alzheimers Res Ther,2022, 14(1): 46.

Shen, X.-N., Li, J.-Q., Wang, H.-F., et al. Plasma amyloid, tau, and neurodegeneration biomarker profiles predict Alzheimer's disease pathology and clinical progression in older adults without dementia [J].Alzheimer's & dementia (Amsterdam, Netherlands),2020, 12(1): e12104-e12104.

Sugarman, M. A., Zetterberg, H., Blennow, K., et al. A longitudinal examination of plasma neurofilament light and total tau for the clinical detection and monitoring of Alzheimer's disease [J].Neurobiology of aging,2020, 94: 60-70.

Therriault, J., Benedet, A. L., Pascoal, T. A., et al. Association of plasma P-tau181 with memory decline in non-demented adults [J].Brain communications,2021, 3(3): fcab136.

Toledo, J. B., Vanderstichele, H., Figurski, M., et al. Factors affecting A beta plasma levels and their utility as biomarkers in ADNI [J].Acta Neuropathologica,2011, 122(4): 401-413.

van Harten, A. C., Jongbloed, W., Teunissen, C. E., et al. CSF ApoE predicts clinical progression in nondemented APOEε4 carriers [J].Neurobiology of aging,2017, 57: 186-194.

Westwood, S., Baird, A. L., Anand, S. N., et al. Validation of plasma proteomic biomarkers relating to brain amyloid burden in the EMIF-Alzheimer's disease multimodal biomarker discovery cohort [J].Journal of Alzheimer's disease,2020, 74(1): 213-225.

Westwood, S., Baird, A. L., Hye, A., et al. Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and F-18 -Flutemetamol PET Scan Result [J].Frontiers in Aging Neuroscience,2018, 10: 409.

Zhao, A., Jiao, Y., Ye, G., et al. Soluble TREM2 levels associate with conversion from mild cognitive impairment to Alzheimer's disease [J].J Clin Invest,2022, 132(24): e158708.

3. Studies included in diagnostic meta.

Cicognola, C., Janelidze, S., Hertze, J., et al. Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment [J].Alzheimers Res Ther,2021, 13(1): 68.

Cullen, N. C., Leuzy, A., Palmqvist, S., et al. Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations [J].Nat Aging,2021, 1(1): 114-123.

Darmanthé, N., Tabatabaei-Jafari, H., & Cherbuin, N. Combination of plasma neurofilament light chain and mini-mental state examination score predicts progression from mild cognitive impairment to alzheimer's disease within 5 years [J].Journal of Alzheimer's disease,2021, 82(3): 951-964.

Fei, M., Jianghua, W., Rujuan, M., et al. The relationship of plasma Aβ levels to dementia in aging individuals with mild cognitive impairment [J].Journal of the Neurological Sciences,2011, 305(1-2): 92-96.

Hanon, O., Vidal, J. S., Lehmann, S., et al. Plasma amyloid beta predicts conversion to dementia in subjects with mild cognitive impairment: The BALTAZAR study [J].Alzheimer's and Dementia,2022, 18(12): 2537-2550.

Janelidze, S., Bali, D., Ashton, N. J., et al. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer's disease [J].Brain,2023, 146(4): 1592-1601.

Kwon, H. S., Kim, J. Y., Koh, S. H., et al. Predicting cognitive stage transition using p-tau181, Centiloid, and other measures [J].Alzheimers Dement,2023, doi: 10.1002/alz.13054.

Pichet Binette, A., Palmqvist, S., Bali, D., et al. Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer's dementia in mild cognitive impairment patients [J].Alzheimers Res Ther,2022, 14(1): 46.

Silva-Spínola, A., Lima, M., Leitão, M. J., et al. Blood biomarkers in mild cognitive impairment patients: Relationship between analytes and progression to Alzheimer disease dementia [J].Eur J Neurol,2023, 30(6): 1565-1573.

Simrén, J., Leuzy, A., Karikari, T. K., et al. The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease [J].Alzheimer's and Dementia,2021, 17(7): 1145-1156.

Xiao, Z., Wu, W., Ma, X., et al. Plasma Aβ42/Aβ40 and p-tau181 Predict Long-Term Clinical Progression in a Cohort with Amnestic Mild Cognitive Impairment [J].Clinical Chemistry,2022, 68(12): 1552-1563.